Achilles Therapeutics Discontinued Its TIL-Based cNeT Program And Closed Phase 1/2A CHIRON and THETIS Trials, And It Will Refocus Its Strategy To Explore Further Engagement With Third Parties, The Company Has Engaged BofA Securities To Provide Strategic Financial Advice
Portfolio Pulse from Benzinga Newsdesk
Achilles Therapeutics has decided to discontinue its TIL-based cNeT program and close its Phase 1/2A CHIRON and THETIS trials. The company plans to refocus its strategy on exploring further engagement with third parties and has engaged BofA Securities for strategic financial advice.
September 19, 2024 | 11:12 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Achilles Therapeutics is discontinuing its TIL-based cNeT program and closing its CHIRON and THETIS trials. The company will now focus on third-party engagements, with BofA Securities providing strategic advice.
The discontinuation of the cNeT program and closure of trials suggest a significant shift in Achilles Therapeutics' strategy, which could lead to short-term negative sentiment. The engagement with BofA Securities indicates a potential strategic pivot, but the immediate impact is likely negative due to halted programs.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100